DrugBank

MARCH 7, 2024

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. adults using obesity medications by 2030, further underlining the growing significance of this sector. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. This has caused a great deal of hesitation from pharmaceutical companies in the past.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

Drug Discovery World

OCTOBER 6, 2022

until 2030. According to Steve Bates OBE, Chief Executive of the BIA: “The UK is a global hub for life sciences, with a world leading academic base, global pharmaceutical players, an increasing manufacturing footprint and a thriving pipeline of innovative SMEs and entrepreneurs.” . Lu Rahman highlights some of the key players. .

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

New Drug Approvals

JANUARY 31, 2024

The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

MAY 15, 2023

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule Teva Pharmaceutical Industries Ltd. Teva is one of the world’s largest manufacturer of generic medicines, making treatments more affordable and accessible.

Government 40

Government Pharmaceuticals Compliance Production 40

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Testimonials 52

The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. Leveraging R&D efforts to address crucial treatment gaps. The company is also committed to ecodesigning all its new products by 2025.

Packaging 52

Packaging Vaccine Disease Treatment 52

Drug Discovery World

FEBRUARY 10, 2023

Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals. Sweden remains Scandinavia’s powerhouse market for pharmaceutical research and development. Sweden remains Scandinavia’s powerhouse market for pharmaceutical research and development.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.  Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15

Pharmaceuticals 78

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 78

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Disease 52

Disease Therapies FDA Trials 52

Vial

MAY 20, 2024

In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Licensing Licensing 40

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. from 2024 to 2030. These services range from clinical study design and data management to statistical analysis and regulatory support.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. Clinical trial sponsors need to coordinate the delivery of investigational medicinal products to clinical sites and the collection of samples from participants after they receive treatment.

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

AUGUST 5, 2021

percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. Baricitinib has not been approved for the treatment of COVID-19, but has been authorized for emergency use by the FDA.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

Drug Discovery World

APRIL 25, 2024

billion in 2022, a figure that is expected to grow at a compound annual growth rate (CAGR) of 9.81% from 2023 to 2030 1. With the pharmaceutical sector increasingly focused on targeted treatments such as antibodies, developers will be more dependent on cell lines. He has a master’s degree in Journalism from Newcastle University.

Vaccine 147

Vaccine Production Pharmaceuticals Therapies 147

Drug Discovery World

MAY 7, 2024

Add to this that the rise of AMR can bring about what the report calls a return to the ‘dark age of medicine’ where surgeries, cancer treatments, even childbirths, become staggeringly more dangerous when there is a lack of effective antibiotics, and it’s easy to understand why there’s such reason for concern.

Vaccine 147

Vaccine Pharmaceutical Companies Clinical Trials Trials 147

Drug Discovery World

APRIL 12, 2023

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. Food and Drug Administration (FDA) for the adjuvant treatment of patients with high-risk melanoma following complete resection.

Vaccine 130

Vaccine Immune Response RNA DNA 130

The Pharma Data

NOVEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” FDA approved Inmazeb for Ebola ( Zaire ebolavirus). Oncology Program.

Production 52

Production FDA FDA Approval Trials 52

Drug Discovery World

JULY 30, 2024

Berkin Gökbudak , Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. When it comes to MDD, the story doesn’t get any easier.

Disease 130

Disease Treatment Science Pharmaceuticals 130

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Drug Discovery World

FEBRUARY 15, 2023

Another revolutionary discovery was the elucidation of the role of IL2 in T cell growth and activation in the 1970s, that later paved the way for the treatment of patients with metastatic melanoma and renal cancer. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research 130

Research Therapies Immune Response Clinical Trials 130

Drug Discovery World

NOVEMBER 18, 2022

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process. .

Pharmaceutical Companies 130

Pharmaceutical Companies Government Pharmaceuticals Hospitals 130

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

FEBRUARY 24, 2022

with more than 8 million cases expected by 2030. with preserved ejection fraction, a form of heart failure that has very limited treatment options.” vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

MARCH 11, 2021

And at Pharmaceuticals, we are seeing success in our late-stage pipeline and are very well positioned with the investments we are making in our future. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. through 2023.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

The Pharma Data

FEBRUARY 8, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. percentage points to 27.1%.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. percentage points to 27.1%.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. An example: For GSPR 12 on devices that incorporate medicinal products, rather than citing the European pharmaceutical regulations (Directive 2001/83/EC), the U.K. government continued to recognize CE-marked products for a limited time.

Regulations 40

Regulations International Government Production 40

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. reflecting lower treatment compliance during the COVID-19 pandemic.

Vaccine 52

Vaccine Production FDA FDA Approval 52